Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trial

Wu Y.-L.Lee J.S.Thongprasert S.CHONG-JEN YUZhang L.Ladrera G.Srimuninnimit V.Sriuranpong V.Sandoval-Tan J.Zhu Y.Liao M.Zhou C.Pan H.Lee V.Chen Y.-M.Sun Y.Margono B.Fuerte F.Chang G.-C.Seetalarom K.Wang J.Cheng A.Syahruddin E.Qian X.Ho J.Kurnianda J.Liu H.E.Jin K.Truman M.Bara I.Mok T.2022-06-272022-06-2720131470-2045https://www.scopus.com/inward/record.uri?eid=2-s2.0-84879784343&doi=10.1016%2fS1470-2045%2813%2970254-7&partnerID=40&md5=e0560f896698da4d8d79ad202911adfchttps://scholars.lib.ntu.edu.tw/handle/123456789/614241Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): A randomised, double-blind trialjournal article10.1016/S1470-2045(13)70254-7237828142-s2.0-84879784343